Treatment of parkinson's disease: Nanostructured sol-gel silica-dopamine reservoirs for controlled drug release in the central nervous system

International Journal of Nanomedicine

Volumn 6, Issue 1, 2011, Pages 19-31

  López, Tessy ^a,b,c   Bata García, José L ^d   Esquivel, Dulce ^b,e   Ortiz Islas, Emma ^b   Gonzalez, Richard ^c   Ascencio, Jorge ^f   Quintana, Patricia ^g   Oskam, Gerko ^g   Álvarez Cervera, Fernando J ^d   Heredia López, Francisco J ^d   Góngora Alfaro, José L ^d  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c TULANE UNIVERSITY   (United States)

^d UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^e UNIVERSITY OF GUANAJUATO   (Mexico)

^f INSTITUTO DE CIENCIAS FÍSICAS   (Mexico)

^g DEPARTAMENTO DE FÍSICA APLICADA   (Mexico)

Author keywords

Central nervous system; Controlled drug release; Parkinson's disease; Reservoirs; Silica dopamine

Indexed keywords

APOMORPHINE; DOPAMINE; NANOCARRIER; NITROGEN; SILICON DIOXIDE; TETRAETHOXYSILANE;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CARBON NUCLEAR MAGNETIC RESONANCE; CENTRAL NERVOUS SYSTEM; CIRCLING BEHAVIOR; CONCENTRATION (PARAMETERS); CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG IMPLANT; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DYSKINESIA; HISTOPATHOLOGY; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MOLECULAR INTERACTION; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; OXIDATION; PARKINSON DISEASE; PARKINSONISM; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; THEORETICAL STUDY; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY;

ANIMALIA; RATTUS;

EID: 79251556891     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S13223     Document Type: Article

References (39)

1. Parkinson J. An Essay on the Shaking Palsy. London, UK: Sherwood Neely and Jones; 1817.
2. Harding AE. Movement disorders. In: Walton J, editor. Brain Diseases of the Nervous System. New York, NY: Oxford University Press; 1993.
3. Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. Can Med Assoc J. 2003; 168:293-301.
4. Paulson GW, Dadmehr N. Is there a premorbid personality typical for Parkinson's disease? Neurology. 1991;41:73-76.
5. Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson's disease. Neurology. 1993;43: 505-508.
6. Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K. Cross cultural traits for personality of patients with Parkinson's disease. Am J Med Genet. 2000;96:1-3.
7. Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology. 1988; 38:1402-1406.
8. Goudreau JL, Ahlskog JE. Symptomatic treatment of Parkinson's disease: Levodopa. In: Ebadi M, Pfeiffer RF, editors. Parkinson's Disease. London: CRC Press; 2005.
9. MA, Morris JG, Reid WG, O'Sullivan DJ, Williamson PM, Rail D. The Sydney multicentre study of Parkinson's disease: A randomised, prospective 5 years study comparing low dose bromocriptine with lowdose levodopa-carbidopa. J Neurol Neurosurg Psychiatr. 1994; 57:903-910.
10. Marsden CD, Parkes JD, Quinn N. Fluctuations in disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, editors. Movement Disorders. London: Butterworths; 1981.
11. García-Escrig M, Bermejo-Pareja F. Complicaciones motoras del tratamiento con levodopa en la enfermedad de Parkinson. Rev Neurol. 1999;28:799-809.
12. Katzung BG. Pharmacological management of Parkinsonism and other movement disorders. In: Basic and Clinical Pharmacology. 8th ed. New York, NY: Lange Medical Books/McGraw Hill Companies Inc; 2001.
13. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107:459-466.
14. Son SJ, Bai X, Lee SB. Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 1. Drug/gene delivery applications. Drug Discov Today. 2007;12:650-656.
15. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: Effect of particle size. Pharm Res. 1996;13:1838-1845.
16. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 1997;14:1568-1573.
17. Barbé C, Bartlett J, Kong L, et al. Silica particles: A novel drug-delivery system. Adv Mater. 2004;16:1959-1966.
18. Slowing I I, Vivero-Escoto J L, Wu ChW, Lin VSY. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60:1278-1288.
19. Rosenholm JM, Lindén M. Toward establishing structure-activity relationships for mesoporous silica in drug delivery applications. J Control Release. 2008;128:157-164.
20. Hirvonen J. Feasibility of silicon and silica-based mesoporous materials for oral drug delivery applications. Eur J Pharm Sci. 2008;9 (34 Suppl):S1.
21. 2 matrices for release of large biologically active molecules. J Sol Gel Sci Technol. 2005;36: 147-156.
22. Lopez T, Ortiz E, Quintana P, Gonzalez RD. A nanostructured titania bioceramic implantable device capable of drug delivery to the temporal lobe of the brain. Colloids Surf A Physicochem Eng Asp. 2007; 3003-3010.
23. 2 nanotubes by TEM. Opt Mater. 2005;27:1270-1275.
24. Avni DA, Coradin T, Lev O, Livage J. Recent bio-applications of sol-gel materials. J Mater Chem. 2006;16:1013-1030.
25. 2 solids for the treatment of temporal lobe epilepsy. Opt Mater. 2006;29:75-81.
26. López T, Quintana P, Martínez JM, Esquivel D. Stabilization of dopamine in nanosilica sol-gel matrix to be used as a controlled drug delivery system. J Non-Cryst Solds. 2007;353:987-989.
27. Nikkhah G, Duan WM, Knappe U, Jödicke A, Björklund A. Restoration of complex sensoriomotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model. Neuroscience. 1993;56:33-43.
28. 2 nanostructured reservoir with temozolomide: Structural evolution of the occluded drug. Opt Mater. 2006;29:88.
29. Paxinos G, Watson W. The Rat Brain in Stereotaxic Coordinates. 2nd ed. San Diego, CA: Academic Press; 1986.
30. Heredia-López FJ, Bata-García JL, Álvarez-Cervera FJ, Góngora- Alfaro JL. A novel rotometer based on a RISC microcontroller. Behav Res Methods Instrum Comput. 2002;34:399-407.
31. Angel-Guío JE, Charris JE, Pérez J, et al. Synthesis and theoretical study of 2-amino-2,3,3a,4,5,6-hexahydro-1H-phenalene and its biological evaluation on central dopaminergic system. Farmaco. 2000;55: 575-582.
32. Aliste MP. Theoretical study of dopamine. Application of the HSAB principle to the study of drug-receptor interactions. THEOCHEM. 2000; 507:1-10.
33. Gregg SG, Sing SW. Adsorption Surface Area and Porosity. 2nd ed. New York, NY: Academic Press; 1982.
34. Barrett EP, Joyner LG, Halenda PJ. The determination of pore volume and area distribution in porous solids. I. Computations from nitrogen isotherms. Am Chem Soc. 1951;73:373-380.
35. Wood DL, Rabinovich EM. Study of alkoxide silica gels by infrared spectroscopy. Appl Spectrosc. 1989;43:263-267.
36. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand. 1971;367:69-93.
37. Hefti F, Melamed E, Wurtman RJ. Partial lesions of the dopaminergic nigrostriatal system in rat brain: Biochemical characterization. Brain Res. 1980;195:123-137.
38. Bata-García JL, Villanueva-Toledo J, Gutiérrez-Ospina G, Alvarez- Cervera FJ, Heredia-López FJ, Góngora-Alfaro JL. Sustained improvement of motor function in hemiparkinsonian rats chronically treated with low doses of caffeine or trihexyphenidyl. Pharmacol Biochem Behav. 2007;86:68-78.
39. Chang JW, Wachtel SR, Young D, Kang UJ. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: Studies on medial forebrain bundle and striatal lesions. Neuroscience. 1999;88:617-628.